Form 4: Acadia Pharmaceuticals Insider Transaction Report

Principal Accounting Officer James Kihara reported the vesting of restricted stock units and a subsequent sale to cover tax obligations.

Summary

• James Kihara, Principal Accounting Officer of Acadia Pharmaceuticals, acquired 2,596 shares of common stock upon the vesting of restricted stock units on May 1, 2026.
• On May 4, 2026, Kihara sold 1,332 shares at a weighted average price of $21.79 per share.
• The sale was executed to satisfy mandatory tax withholding obligations related to the vesting event.
• Following these transactions, Kihara holds 29,129 shares of Acadia Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction is purely administrative and related to tax obligations rather than a discretionary change in investment sentiment.

Positives

• The transaction reflects the standard vesting of equity compensation, indicating ongoing alignment between management and shareholder interests.

Negatives

• The sale of shares, while tax-related, reduces the direct equity stake held by the Principal Accounting Officer.

Risks

• Market volatility could impact the value of remaining equity holdings.
• Reliance on equity-based compensation may be affected by future stock price performance.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Management Comments

• The reporting person confirmed that the sale was made to cover withholding taxes and tax-related items in connection with the vesting of restricted stock units.

Industry Context

StockSavvy.ai notes that this is a routine administrative filing common in the biotechnology sector, where equity-based compensation is a standard component of executive remuneration packages.

Comparison to Industry Standards

• The transaction follows standard industry practices for tax-related sell-to-cover events.
• The use of Rule 10b5-1(c) plans is consistent with best practices for corporate insiders to avoid potential conflicts of interest.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was a pre-planned tax-related sale.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

ACAD, Acadia Pharmaceuticals, Insider Trading, Form 4, Equity Compensation, Principal Accounting Officer